{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:30:18Z","timestamp":1791469818350,"version":"4.3.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T00:00:00Z","timestamp":1596844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T00:00:00Z","timestamp":1596844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s00774-020-01137-7","type":"journal-article","created":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T18:03:36Z","timestamp":1596909816000},"page":"903-907","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Intrafamilial phenotypic distinction of hypophosphatasia with identical tissue nonspecific alkaline phosphatase gene mutation: a family report"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2023-6585","authenticated-orcid":false,"given":"Masaru","family":"Kato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Ninagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimi","family":"Izumihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhide","family":"Tanimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,8]]},"reference":[{"key":"1137_CR1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X19863997","author":"V Choida","year":"2019","unstructured":"Choida V, Bubbear JS (2019) Update on the management of hypophosphatasia. Ther Adv Musculoskelet Dis. https:\/\/doi.org\/10.1177\/1759720X19863997","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"1137_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.bone.2013.01.024","volume":"54","author":"KE Berkseth","year":"2013","unstructured":"Berkseth KE, Tebben PJ, Drake MT, Hefferan TE, Jewison DE, Wermers RA (2013) Clinical spectrum of hypophosphatasia diagnosed in adults. Bone 54:21\u201327","journal-title":"Bone"},{"key":"1137_CR3","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1007\/s00198-017-4087-z","volume":"28","author":"T Schmidt","year":"2017","unstructured":"Schmidt T, Mussawy H, Rolvien T, Hawellek T, Hubert J, Ruther W, Amling M, Barvencik F (2017) Clinical, radiographic and biochemical characteristics of adult hypophosphatasia. Osteoporos Int 28:2653\u20132662","journal-title":"Osteoporos Int"},{"key":"1137_CR4","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/ejhg.2014.10","volume":"22","author":"C Hofmann","year":"2014","unstructured":"Hofmann C, Girschick H, Mornet E, Schneider D, Jakob F, Mentrup B (2014) Unexpected high intrafamilial phenotypic variability observed in hypophosphatasia. Eur J Hum Genet 22:1160\u20131164","journal-title":"Eur J Hum Genet"},{"key":"1137_CR5","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1002\/jbmr.1565","volume":"27","author":"RA Sutton","year":"2012","unstructured":"Sutton RA, Mumm S, Coburn SP, Ericson KL, Whyte MP (2012) \u201cAtypical femoral fractures\u201d during bisphosphonate exposure in adult hypophosphatasia. J Bone Miner Res 27:987\u2013994","journal-title":"J Bone Miner Res"},{"key":"1137_CR6","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1002\/jbmr.2495","volume":"30","author":"T Cundy","year":"2015","unstructured":"Cundy T, Michigami T, Tachikawa K, Dray M, Collins JF, Paschalis EP, Gamsjaeger S, Roschger A, Fratzl-Zelman N, Roschger P, Klaushofer K (2015) Reversible deterioration in hypophosphatasia caused by renal failure with bisphosphonate treatment. J Bone Miner Res 30:1726\u20131737","journal-title":"J Bone Miner Res"},{"key":"1137_CR7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jbspin.2017.12.001","volume":"85","author":"M Righetti","year":"2018","unstructured":"Righetti M, Wach J, Desmarchelier R, Coury F (2018) Teriparatide treatment in an adult patient with hypophosphatasia exposed to bisphosphonate and revealed by bilateral atypical fractures. Joint Bone Spine 85:365\u2013367","journal-title":"Joint Bone Spine"},{"key":"1137_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1006\/mgme.2001.3283","volume":"75","author":"S Mumm","year":"2002","unstructured":"Mumm S, Jones J, Finnegan P, Henthorn PS, Podgornik MN, Whyte MP (2002) Denaturing gradient gel electrophoresis analysis of the tissue nonspecific alkaline phosphatase isoenzyme gene in hypophosphatasia. Mol Genet Metab 75:143\u2013153","journal-title":"Mol Genet Metab"},{"key":"1137_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1471-2350-10-51","volume":"10","author":"D Fauvert","year":"2009","unstructured":"Fauvert D, Brun-Heath I, Lia-Baldini AS, Bellazi L, Taillandier A, Serre JL, de Mazancourt P, Mornet E (2009) Mild forms of hypophosphatasia mostly result from dominant negative effect of severe alleles or from compound heterozygosity for severe and moderate alleles. BMC Med Genet 10:51","journal-title":"BMC Med Genet"},{"key":"1137_CR10","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1002\/humu.24010","volume":"41","author":"G Del Angel","year":"2020","unstructured":"Del Angel G, Reynders J, Negron C, Steinbrecher T, Mornet E (2020) Large-scale in vitro functional testing and novel variant scoring via protein modeling provide insights into alkaline phosphatase activity in hypophosphatasia. Hum Mutat. 41:1250\u20131262","journal-title":"Hum Mutat"},{"key":"1137_CR11","doi-asserted-by":"publisher","first-page":"51569","DOI":"10.18632\/oncotarget.18093","volume":"8","author":"J Wan","year":"2017","unstructured":"Wan J, Zhang L, Liu T, Wang Y (2017) Genetic evaluations of Chinese patients with odontohypophosphatasia resulting from heterozygosity for mutations in the tissue-non-specific alkaline phosphatase gene. Oncotarget 8:51569\u201351577","journal-title":"Oncotarget"},{"key":"1137_CR12","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1359\/JBMR.041229","volume":"20","author":"M Goseki-Sone","year":"2005","unstructured":"Goseki-Sone M, Sogabe N, Fukushi-Irie M, Mizoi L, Orimo H, Suzuki T, Nakamura H, Orimo H, Hosoi T (2005) Functional analysis of the single nucleotide polymorphism (787T>C) in the tissue-nonspecific alkaline phosphatase gene associated with BMD. J Bone Miner Res 20:773\u2013782","journal-title":"J Bone Miner Res"},{"key":"1137_CR13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1385\/BTER:104:2:131","volume":"104","author":"DN Vaisman","year":"2005","unstructured":"Vaisman DN, McCarthy AD, Cortizo AM (2005) Bone-specific alkaline phosphatase activity is inhibited by bisphosphonates: role of divalent cations. Biol Trace Elem Res 104:131\u2013140","journal-title":"Biol Trace Elem Res"},{"key":"1137_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocd.2018.12.006","author":"E Lefever","year":"2018","unstructured":"Lefever E, Witters P, Gielen E, Vanclooster A, Meersseman W, Morava E, Cassiman D, Laurent MR (2018) Hypophosphatasia in adults: clinical spectrum and its association with genetics and metabolic substrates. J Clin Densitom. https:\/\/doi.org\/10.1016\/j.jocd.2018.12.006","journal-title":"J Clin Densitom"},{"key":"1137_CR15","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1136\/ard.29.5.537","volume":"29","author":"MJ Kendall","year":"1970","unstructured":"Kendall MJ, Cockel R, Becker J, Hawkins CF (1970) Raised serum alkaline phosphatase in rheumatoid disease. an index of liver dysfunction? Ann Rheum Dis 29:537\u2013540","journal-title":"Ann Rheum Dis"},{"issue":"Pt 4","key":"1137_CR16","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1177\/000456329503200405","volume":"32","author":"C Beyeler","year":"1995","unstructured":"Beyeler C, Banks RE, Thompson D, Forbes MA, Cooper EH, Bird H (1995) Bone alkaline phosphatase in rheumatic diseases. Ann Clin Biochem 32(Pt 4):379\u2013384","journal-title":"Ann Clin Biochem"},{"key":"1137_CR17","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00198-018-4691-6","volume":"30","author":"JM Colazo","year":"2019","unstructured":"Colazo JM, Hu JR, Dahir KM, Simmons JH (2019) Neurological symptoms in hypophosphatasia. Osteoporos Int 30:469\u2013480","journal-title":"Osteoporos Int"},{"key":"1137_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1136\/archdischild-2013-305037","volume":"99","author":"T Taketani","year":"2014","unstructured":"Taketani T, Onigata K, Kobayashi H, Mushimoto Y, Fukuda S, Yamaguchi S (2014) Clinical and genetic aspects of hypophosphatasia in Japanese patients. Arch Dis Child 99:211\u2013215","journal-title":"Arch Dis Child"},{"key":"1137_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00223-019-00626-w","volume":"106","author":"T Michigami","year":"2020","unstructured":"Michigami T, Tachikawa K, Yamazaki M, Kawai M, Kubota T, Ozono K (2020) Hypophosphatasia in Japan: ALPL mutation analysis in 98 unrelated patients. Calcif Tissue Int 106:221\u2013231","journal-title":"Calcif Tissue Int"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-020-01137-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-020-01137-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-020-01137-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T23:29:31Z","timestamp":1628378971000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-020-01137-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,8]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["1137"],"URL":"https:\/\/doi.org\/10.1007\/s00774-020-01137-7","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,8]]},"assertion":[{"value":"18 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Masaru Kato has received research grants from AbbVie, Actelion, and GlaxoSmithKline and speaking fees from Eli Lilly. Tatsuya Atsumi has received research grants from Astellas, Takeda, Mitsubishi Tanabe, Chugai, Daiichi-Sankyo, Otsuka, Pfize, Alexion, Bayer, Otsuka, Chugai, Takeda, Eisai, Bristol-Myers Squibb, Daiichi Sankyo, Mitsubishi Tanabe and AsahiKasei, consultant fees from Ono, Sanofi, Daiichi Sankyo and Pfizer and speaking fees from Mitsubishi Tanabe, Chugai, Astellas, Takeda, Pfizer, Daiichi Sankyo, Bristol-Myers Squibb and Eli Lilly. Other authors have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}